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ABSTRACT  
Protein-conjugated magnetic nanoparticles (mNPs) are promising tools for a variety of biomedical 
applications, from immunoassays and biosensors to theranostics and drug-delivery. In such 
applications, conjugation of affinity proteins (e.g., antibodies) to the nanoparticle surface many 
times compromises biological activity and specificity, leading to increased reagent consumption 
and decreased assay performance. To address this problem, we engineered a biomolecular 
magnetic separation system that eliminates the need to chemically modify the capture 
biomolecules with nanoparticles or synthetic polymers of any kind. The system consists of (i) 
thermo-responsive magnetic iron oxide nanoparticles displaying poly(N-isopropylacrylamide) 
(pNIPAm), and (ii) an elastin-like polypeptide (ELP) fused with the affinity protein Cohesin (Coh). 
Proper design of pNIPAm-mNPs and ELP-Coh allowed for efficient cross-aggregation of the two 
distinct nanoparticle types under collapsing stimuli, which enabled magnetic separation of ELP-
Coh aggregates bound to target Dockerin (Doc) molecules. Selective re-solubilization of the ELP-
Coh:Doc complexes was achieved under intermediate conditions under which only the pNIPAm-
mNPs remained aggregated. We show that ELP-Coh is capable of magnetically separating and 
purifying nanomolar quantities of Doc as well as eukaryotic whole cells displaying the 
complementary Doc domain from diluted human plasma. This modular system provides magnetic 
enrichment and purification of captured molecular targets, and eliminates the requirement of bio-
functionalization of magnetic nanoparticles to achieve bioseparations. Our streamlined and 
simplified approach is amenable for point-of-use applications and brings the advantages of ELP-
fusion proteins to the realm of magnetic particle separation systems. 
KEY WORDS: ELP, cross-aggregation, magnetic nanoparticle, molecule/cell capture, pNIPAm.  
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Interdisciplinary efforts in the fields of protein engineering, nanomaterials, and polymer 
chemistry are advancing bioseparation technology in ways not previously thought possible. New 
compositions of stimuli-responsive polymers, nanoparticles and proteins are being rationally 
designed to perform precise tasks and directed interactions inside complex biological fluids. Both 
magnetic nanoparticles1–6 and stimuli-responsive polymers have proven extremely useful 
independently, as well as in combination5–11 for the separation of biomolecules and cells from 
blood, saliva and urine for use in biosensors, and immunoassay systems.  
When designing separation systems for bioassays, it is important to acknowledge the inherent 
trade off between the size of the capture reagents, and the mechanisms by which they can be 
separated from biological fluids. Several factors can be considered when rating the performance 
of a biological separation system. The size of reagents, their tendency to undergo non-specific 
interactions with sample matrix components, and their diffusivity all have strong effects on assay  
performance. These performance parameters can be evaluated to determine how to optimize 
features such as the speed of separation, efficiency, sensitivity and specificity for a given 
application.  
Magnetic particles are straightforward to separate using simple rare earth magnets12–16. When 
affinity biomolecules such as antibodies or oligonucleotides are conjugated to magnetic 
nanoparticles and bound to their targets, a magnetic force applied to the nanoparticle is transmitted 
through the chemical linkages of the polymer tether/antibody, and exerted along the non-covalent 
binding interface to the target. By such means, protein targets are subjected to magnetic forces 
which actuate them within a liquid medium against Brownian forces. This separation mechanism 
has created an interest in bioconjugate techniques to immobilize capture biomolecules onto the 
surfaces of magnetic particles.17 However, in many cases, immobilization of biomolecules onto 
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nanoparticle surfaces can compromise binding activity,18,19 especially in the case of chemical 
conjugation to particles in which random immobilization might result in interference with the 
active site and/or hindering its accessibility to the analytes.20 Van Leemputten and Horisberger21 
and Kazenwadel et al.22 reported that coupling of enzymes (trypsin, glucose oxidase, horseradish 
peroxidase, etc) onto magnetic particles resulted in significant activity loss down to 35-0.1%, 
depending on the particle to enzyme ratios used. Immobilization of antibodies also was found to 
decrease their binding activity from slight reduction to complete loss, depending on the methods 
used.23,24 In general, the immobilization of proteins onto nanoparticle surfaces inhibits bioactivity, 
is time- and labor-consuming, and cost intensive. 
Magnetic separation of small microparticles on the order of hundreds of nanometers to 
micrometers can be achieved rapidly in seconds. Such particles, however, exhibit lower specific 
surface area to volume ratios than smaller nanoparticles on the order of 10 nm, which lowers the 
binding capacity per gram. Larger particles also require longer to reach equilibrium and may not 
bind bulky targets (e.g., large proteins and cells) as compared with small nanoparticles due to 
significant steric hindrance. Alternatively, small nanoparticles on the order of 10s of nanometers 
will bind bulky targets with essentially diffusion-limited reaction rates, and reach equilibrium 
quickly. The challenge, however, is that 10 nm particles are difficult to magnetically separate 
because thermal Brownian forces overwhelm the magnetic forces which scale with the particle 
volume. This inherent paradox for magnetic separation systems has created a strong need for 
systems that can combine the rapid binding kinetics of small molecular-scale capture reagents with 
the ease of rapid separation in a modest magnetic field.  
Stimuli-responsive polymers have also played an important role in bioseparations. Bio-
conjugated poly(N-isopropylacrylamide),25-29 poly(oligoethylene glycol),30,31 and elastin-like 
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polypeptides,32 for example, have all been utilized as capture reagents for thermo-precipitation and 
biosensing.33–35 Separation is achieved by raising the sample temperature above the lower critical 
solution temperature (LCST) to create insoluble polymer aggregates, which can be separated using 
a centrifugal field. Such systems can achieve sensitive detection of biomarkers, however, the 
requirement of centrifugal fields may be limiting in certain settings. For resource limited settings, 
ideally a testing system could be administered without the need for a central lab facility or even 
electricity, eliminating the possibility of using centrifugal fields. Therefore, in specific applications 
magnetic particles are highly advantageous because they can be separated without requiring a 
centrifuge. 
Elastin-like polypeptides (ELPs) are biological protein polymers consisting of repetitive 
(VPGXG)n sequences, where X comprises any natural guest amino acid residue excluding proline. 
Like their synthetic smart polymer counterparts, ELPs show LCST behavior with the added benefit 
of being programmed at the genetic level and therefore completely monodisperse. Another 
advantage of ELP systems is the ability to genetically fuse ELP-tags to a protein of interest through 
a cleavable linker.36 The fusion domain can be thermo-precipitated from a sample fluid and cleaved 
from the ELP, or bound to a specific target to achieve affinity separation. This separation 
mechanism, however, suffers from the same limitations as synthetic polymer thermo-precipitation 
systems by requiring a centrifugal field. Although filtration membranes can in principle work, 
volumetric throughput is limited in such systems.34 
Here we sought to combine the advantages of ELP-fusion proteins with the ease of magnetic 
particle separations. Our system addresses several of the existing limitations of bioseparation 
technologies by demonstrating the cross-aggregation of pNIPAm-mNPs with ELPs, followed by 
magnetic separation of the co-entrained ELPs. This simple yet effective strategy enabled rapid 
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magnetic enrichment of molecular and cellular targets that were bound to ELP-receptor fusions. 
Our approach eliminates the need to modify the magnetic particles with capture biomolecules, and 
extends the advantages of ELPs into the realm of magnetic targeting and bioseparations.    
To design an effective magnetic capture system for ELPs, we produced mNPs decorated with a 
10 kDa pNIPAm containing a dodecyl hydrocarbon tail and a terminal carboxyl group. We 
synthesized these polymers via RAFT polymerization, and used them as colloidal stabilizing 
agents for iron oxide particle synthesis through thermal decomposition of iron pentacarbonyl. The 
resulting mNP morphology was characterized by TEM (Figure 1A), with particle diameters of ~10 
nm, consistent with previous reports.5,6,8,9 The thermally-responsive pNIPAm chains remained on 
the crystalline nanoparticle surface following purification by dialysis. Raising the temperature 
above the LCST of pNIPAm resulted in aggregation of the mNPs and clouding up of the solution. 
In the presence of a strong magnet below the LCST, the mNPs were found to be non-responsive 
on a timescale of 30 min. Upon raising the temperature above the LCST or upon addition of salt, 
mNP aggregates were rapidly formed and magnetophoresed to the side of the reaction vessel on a 
timescale of 1 minute. This property of aggregation-dependent magnetophoresis served for us as 
inspiration for a new approach to bioseparations, whereby other polymers from solution (free 
polymers) could be entrained within magnetic particle aggregates.  
For our capture-and-release system to function properly, it was necessary to have an orthogonal 
stimulus to control the aggregation properties of one particle type in relation to the other. By 
incorporating pH-responsive glutamate into 20% of the guest residue positions of the ELP (see full 
sequences in Supporting Information), we could use buffer pH-switching to easily raise and lower 
the LCST of the ELP conjugates. The pNIPAm chains on the mNPs each contained a single 
carboxyl group which responds only very weakly to pH. This difference in the pH-dependent 
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aggregation profiles was used to release the ELP conjugates while keeping the mNPs collapsed in 
the second step of the assay. The final ELP guest residue composition used for this work was 
(M1V7E2) repeated either 9 or 12 times.  
As a fusion partner for the ELP, we selected the second Cohesin (Coh) domain from scaffold A 
of the cellulolytic complex from Clostridium thermocellum. This domain is known to be very 
stable and binds with high affinity to many different type-I Dockerin (Doc) domains with KD 
values of ~1-10 nM. 37-40 The Docs themselves are short 8-kDa calcium-binding domains that fold 
into a duplicated F-hand motif. With a length of ~75 amino acids and ~2 nm folded size, Doc 
domains are suitable for incorporation as affinity tags when fused with fluorescent protein 
domains, or in cellular display systems as described below.  
Sub-cloning of the gene for Cohesin at the C-terminus of the (M1V7E2)9 and (M1V7E2)12 ELP 
genes, followed by over expression in E. coli yielded ~25 mg of  ELP-Coh fusion proteins per liter 
of E. coli culture, which were purified via a non-chromatographic inverse transition cycle 
purification protocol. Protein characterization was performed using gel electrophoresis and size 
exclusion chromatography as shown in Figure S2, Supporting Information.  
The cloud point curves for the mNPs, (M1V7E2)9-Coh, and (M1V7E2)12-Coh (Figures 1B and 1C) 
demonstrate the mechanism by which coordinated or differential magnetic actuation of the 
pNIPAm-mNPs/ELP-Coh system could be achieved depending on the environmental stimuli. 
Increasing the ionic strength by addition of NaCl shifted the LCST to lower temperatures (Figure 
1C) uniformly for both the ELP-Cohs and pNIPAm-mNPs, whereas lowering the pH only shifted 
the LCST of ELP-Coh. As shown in Figure 1B, at neutral pH ELP-Coh had an LCST of >60 °C, 
whereas pNIPAm-mNPs exhibited an LCST of <50 °C. Meanwhile, dropping the pH to 4.5 
protonated the glutamic acid guest residues and decreased the electrostatic repulsion of ELP-Coh, 
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reducing the LCST to <C to a point where they could be co-collapsed with pNIPAm-mNPs. Thus, 
the combined stimulus of pH 4.5 and 0.5 M NaCl in 20 mM acetate buffer was found to be effective 
for co-collapse of pNIPAm-mNPs and ELP-Coh. The design of the materials was critical in this 
case for achieving conditions for co-collapse of pNIPAm-mNPs and ELP-Coh that was not overly 
harsh so as to disrupt the Coh protein structure, inhibit binding interactions, or in the case of cell 
separation (see below) harm cell viability. In addition to providing molecular specificity, ELP-Coh 
also served as a ‘free’ polymer to enhance the aggregation process, as was previously reported for 
pNIPAm-coated gold nanoparticles.41 The co-aggregation of the pNIPAm-mNPs and ELP is based 
on hydrophobic interactions. On one hand, at low pH the glutamic acid residues of the ELP and 
the end-carboxyl groups of the pNIPAm become protonated, which decreases electrostatic 
repulsion between the two smart polymer types in collapsing buffer. On the other hand, the 
‘salting-out’ effect at high NaCl concentration remarkably reduces the protein and pNIPAm 
solubility, leading to hydrophobic collapse and coordinated aggregation of pNIPAm and ELPs. 
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Figure 1. (A) TEM image of pNIPAm-mNPs. (B) Cloud-point assay showing responsive 
characteristics of pNIPAm-mNPs and ELP-Coh upon changes in pH. (C) Cloud-point assay 
showing responsive characteristics of pNIPAm-mNPs and ELP-Coh upon changes in salt 
concentration. (D) Protein quantification during co-collapse, washing, and release of the pNIPAm-
mNPs and ELP-Coh. The non-captured, washed, and released supernatants were collected in 
‘Sup1’, ‘Wash’ and ‘Sup2’ fractions, respectively. The protein contents of each fraction was 
determined by BCA assay and normalized to the initial ELP-Coh quantity (0.5 mg). SDS-PAGE 
analysis of each fraction is displayed on top.  
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In contrast to the mNPs, ELP-Coh remained soluble at 40 oC in PBS pH 7.4 containing 0.5 M 
NaCl, while the mNPs remained aggregated. The releasing buffer at 40 °C pH 7.4 was therefore 
used for recovery of soluble ELP-Coh from aggregated pNIPAm-mNPs.  
To test the ability of smart magnetic nanoparticles to co-aggregate with ELPs and affect 
magnetic actuation of proteins, a pNIPAm-mNPs and ELP-Coh mixture was collapsed at 40°C in 
collapsing buffer and magnetically separated for ~1 min. We found that approximately 75% of the 
ELP-Coh proteins could be co-collapsed with pNIPAm-mNPs and recovered in soluble form as 
determined by BCA assay (Figure 1D). We found no significant differences in magnetic separation 
characteristics between (M1V7E2)9-Coh and (M1V7E2)12-Coh, and so only the (M1V7E2)9-Coh was 
used for further biomolecule and whole cell capture experiments as described below.  
As a model biomarker, we produced and purified a fusion protein of the fluorescent iLOV 
domain42 and a type-I Dockerin module (iLOV-Doc). Binding of the engineered ELP-Coh to the 
fluorescent iLOV-Doc was firstly confirmed by size-exclusion chromatography (SEC) (Figure S2, 
Supporting Information). We then challenged the mixture of pNIPAm-mNPs and ELP-Coh with 
fishing out iLOV-Doc (Figure 2A) from clean buffers, 20 μg/ml BSA-buffer solutions, and 10% 
human plasma samples (Figure 3) while tracking the capture efficiency by measuring the 
fluorescence intensity. In clean buffers, a simple procedure involving co-collapse of the pNIPAm-
mNPs and the ELP-Coh:iLOV-Doc complexes followed by application of a magnetic field was 
able to capture a majority (~85 - 90%) of iLOV-Doc in a 5 µM solution. The captured aggregate 
was then re-solubilized with releasing buffer (fraction ‘Sup2’), resulting in an overall capture-and-
release efficiency of ~75% (Figure 2B). In contrast, we used Coh-iLOV as a negative control and 
found that it could not be efficiently separated by the pNIPAm-mNPs and ELP-Coh mixture, 
appearing in the ‘Sup1’ non-captured fraction (Figure 2B). We note that the sum of fluorescent 
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intensities of all three fractions (Sup1, Wash, Sup2) from each treatment in which iLOV-Doc or 
Coh-iLOV was mixed with the ELP-Coh and/or mNPs was slightly lower than the total fluorescent 
intensity of pure iLOV-Doc or Coh-iLOV (Figure S5, Supporting information) treated with the 
same 40 °C collapsing buffer. This may be due to fluorescence quenching effects of iLOV-Doc 
inside the aggregates. This effect served to lower our observed capture efficiency, therefore our 
reported capture efficiencies should be considered a lower bound. 
The fluorescent data of captured iLOV-Doc was in accordance with SDS-PAGE result (Figure 
2C). Without pNIPAm-mNPs, the ELP-Coh:iLOV-Doc complexes could still be collapsed, 
however, they were not captured by the magnetic field and thus were removed in the ‘Sup1’ non-
captured fraction. In addition, solutions with initially low concentrations of iLOV-Doc could 
significantly be enriched by resuspending the captured aggregates into smaller volumes of 
releasing buffer. When proteins such as BSA were spiked into the initial samples together with 
iLOV-Doc, magnetic separation of ELP-Coh:iLOV-Doc successfully depleted a majority of the 
nonspecific background proteins (Figure 2D and 2E). Notably, a collapsing and separation time as 
short as 1 min was sufficient for effective capture of iLOV-Doc.  
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Figure 2. Magnetic separation of iLOV-Doc by ELP-Coh and pNIPAm-mNPs. (A) Scheme 
depicting reagent system for specific capture and magnetic separation of iLOV-Doc. The 
magnetophoretic procedure has four steps: i) pNIPAm-mNPs and ELP-Coh are mixed in a fluid 
containing the target (iLOV-Doc) and background proteins; ii) the ELP-Coh specifically binds 
iLOV-Doc in the mixture, forming ELP-Coh:iLOV-Doc complexes; iii) co-collapse of pNIPAm-
mNPs and ELP-Coh occurs upon application of temperature, pH, and/or ionic stimuli. A magnet 
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placed against the side of the reaction vessel separates ELP-Coh:iLOV-Doc complexes together 
with pNIPAm-mNPs; iv) Reversal of the stimulus releases only the ELP-Coh:iLOV-Doc 
complexes whilst keeping the pNIPAm-mNPs collapsed. (B) Relative fluorescence of the non-
captured fraction (Sup1), washed fraction (Wash), and released fraction (Sup2) under different 
treatment conditions. Fluorescence was normalized to the sample containing pure iLOV-Doc (5 
µM). Coh-iLOV was used as a non-binding control. (C) SDS-PAGE profiles of protein fractions 
displayed in (B). (D) Enrichment of 0.05 µM iLov-Doc by combining five captured fractions into 
a single aliquot of release buffer. (E) SDS-PAGE analysis of samples before and after enrichment. 
Pure ELP-Coh, iLOV-Doc and BSA were loaded as controls. 
 
Capture of iLOV-Doc in diluted plasma was performed similarly with some modification to the 
collapsing conditions. Since Ca2+ is required for correct folding of the Doc domain, additional Ca2+ 
(5 mM) was supplemented for all experiments performed in 10% plasma to compensate for the 
loss of these ions due to an abundance of Ca2+-binding proteins in plasma. Moreover, 2x collapsing 
buffer was used to overcome the intrinsic buffering capacity of the plasma and maintain the pH at 
4.5. Figure 3 shows that up to 80% of the target iLOV-Doc protein could be recovered from 10% 
plasma following magnetic processing with pNIPAm-mNPs. At iLOV-Doc concentrations higher 
than 1 μM, the capture efficiency decreased slightly to >70%. These findings demonstrate the 
capability of the pNIPAm-mNPs/ELP-Coh system for specific capture of the target protein in 
biological samples at an appropriate dilution. The same samples that were processed and quantified 
for iLOV-Doc fluorescence were also analyzed using SDS-PAGE (Figure 3B) which showed that 
the majority of the background plasma proteins were removed following magnetic processing. 
Magnetic separation of ELP-Coh was found to be especially effective at removing large molecular 
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weight plasma proteins, while some albumin was nonspecifically captured and transferred together 
with iLOV-Doc. Fluorescence imaging of iLOV-Doc fluorescence in the SDS-PAGE gel is shown 
in the bottom of Figure 3B.  
 
Figure 3. Capture of iLOV-Doc in diluted human plasma. (A) Fluorescent intensity of iLOV-Doc 
measured before capture in TBS-Ca + 10% human blood plasma, and after capture in releasing 
buffer. The fluorescence intensity was blanked by subtracting the intensity of pure buffer or buffer 
+ 10% human blood plasma. (B) SDS-PAGE gel and fluorescent visualization of samples with 
different iLOV-Doc concentrations before and after capture. Pure iLOV-Doc (5 μM) in clean 
buffer was used as control. 
 
To test cell capture, we created a yeast model displaying Doc fusion proteins by cloning GFP-
Doc or iLOV-Doc genes into a pYD1 yeast display plasmid. Expression levels were found to be 
slightly higher for GFP-Doc, and so only GFP-Doc was used for further testing, although both cell 
types were successfully captured by the pNIPAm-mNPs and ELP-Coh (Figure S4, panel A-C). 
Display of GFP-Doc through the Aga1p-Aga2p system was complete 40 hours post-induction. 
Antibody staining for the XPress-tag located between the Aga2p domain and the GFP-Doc showed 
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that approximately 60% of the cell population was positive for display on the outer cell wall 
(Figure S4, panel D, Supporting information), which is a typical percentage of cells successfully 
induced using this display system.43 For cell capture experiments, the highest achievable fraction 
of GFP-Doc positive cells was therefore 60%. We added ELP-Coh and pNIPAm-mNPs into cell 
suspensions, triggered the phase separation with collapsing buffer, and separated the aggregates 
with a magnet (Figure 4A). Three fractions (Sup1, Wash, Sup2) were collected and analyzed with 
flow cytometry. The results in Figure 4B (left panel) showed that ~50 - 60% of non-displaying 
(wild-type) cells were removed in the non-captured Sup1 and Wash fractions, while approximately 
71.4 % of the GFP-Doc target cells were captured. 
In order to demonstrate the ability of the pNIPAm-mNPs and ELP-Coh system to specifically 
capture target cells with low abundance in a heterogeneous population, serial dilutions of the GFP-
Doc-displaying cells were prepared by addition of wild-type negative yeast cells while maintaining 
the total cell number at ~6.25 x 106 cells/mL for binding with the ELP-Coh prior to magnetic 
separation. The cell capture experiments were first conducted in clean buffer. Capture of the GFP-
Doc displaying cells was performed using collapsing buffer and magnetic separation. The captured 
cell fractions were then analyzed using flow cytometry. The cell capture efficiency and the 
enrichment factors were plotted in Figure 4C (left panel) as a function of the fraction GFP-Doc 
positive cells in the original sample. For samples with a GFP-Doc positive cell fraction <15%, we 
found the highest capture efficiencies of up to ~100%, e.g. for a starting sample with 1% GFP-
positive cells. In addition, the target cell population could be enriched by a factor up to 2.5, 
especially for samples with a low fraction of GFP-Doc target cells. Capture efficiency and 
enrichment factor subsequently decreased with a higher percentage of GFP-positive cells (>15%) 
(Figure S6, Supporting information). 
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Figure 4. Capture of yeast cells displaying GFP-Doc using pNIPAm-mNPs/ELP-Coh system. (A) 
Scheme depicting reagent system for specific capture and magnetic separation of yeast cells 
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displaying GFP-Doc. The magnetophoretic procedure has four steps as described for capturing 
free iLOV-Doc. (B) GFP-Doc positive and negative cell count in different fractions after 
separation. The non-captured cells were collected in ‘Sup1’ and ‘Wash’ fractions using collapsing 
buffer, whereas the captured cells were obtained with releasing buffer in the ‘Sup2' fraction. Non-
displaying wild-type (WT) cells were used as a negative control. (C) Cell capture efficiency and 
enrichment factor for target cells at different abundance levels. For figures B and C, the left panels 
show samples prepared in TBS-Ca buffer, while the right panels show samples prepared in TBS-
Ca buffer supplemented with 10% human blood plasma. (D) Flow-cytometry results for a sample 
with approximately ~1.1% target cells in the original sample (defined by the red gate). After 
capture and separation by the pNIPAm-mNPs/ELP-Coh system, analytical flow cytometry 
demonstrated a capture efficiency of ~100% as well as a 2.4-fold enrichment of target cells above 
the background, while the number of non-displaying negative cells was reduced by more than 
50%. 
 
To mimic a more realistic clinical sample matrix, we utilized the pNIPAm-mNPs/ELP-Coh 
system for capturing cells from diluted 10% human plasma, resulting in similar capture efficiencies 
(Figure 4B, C right panels). The pNIPAm-mNPs/ELP-Coh system thus showed specificity for 
binding to GFP-Doc displayed on the yeast cell wall in the presence of high levels of plasma 
proteins. For capturing cells from dilute plasma, the same modifications to the collapsing 
conditions were applied as were done for capturing free iLOV-Doc in diluted plasma sample (i.e., 
increased Ca2+ and increased collapsing buffer concentration). A representative cell capture result 
from 10% plasma is shown in Figure 4D in which a starting sample (~6.25 x 106 cells/mL of TBS 
+ 10% plasma) containing ~1.1% GFP-Doc displaying cells was subjected to magnetophoresis 
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using the pNIPAm-mNPs/ELP-Coh system. The captured cells were suspended into the same 
volume. In this case, ~90% of the GFP-Doc cells were captured and the percentage of these cells 
in the resulting population was increased to ~2.6% (2.4-fold enrichment). When viewed from the 
point of view of the background cells, about 1.5 x 105/mL GFP-Doc negative cells were in the 
original sample, while in the Sup2 fraction, this number was reduced to 0.7 x 105/mL, representing 
removal of more than 50% background cells.  
Minimizing non-specific carryover of target molecules and cells is a challenge for smart 
polymer-based affinity separations, as is the case for all bioseparation systems. We noticed carry-
over of BSA (or human serum albumin) when capturing and enriching free iLOV-Doc from buffers 
and diluted plasma (Figure 2D and 3B), as well as a ~50% carryover of GFP-Doc negative cells 
(Figure 4D) that were separated along with GFP-Doc displaying cells. This nonspecific carryover 
is attributed to hydrophobic interactions between background proteins and pNIPAm-mNPs/ELP 
aggregates, while in the case of cellular capture, physical entanglement of cells inside pNIPAm-
mNPs/ELP-Coh aggregates is thought to be the cause. Despite these limitations, specificity of 
binding and capturing was still found to be rapid and robust. Additionally, our presented systems 
has improved simplicity as compared to classical magnetic separation process. Our system 
eliminates both the requirement for bioconjugation of any receptors to nanoparticles and eliminates 
the centrifugal separation step. These combined advantages make it feasible and attractive among 
existing immunoseparation techniques.44 We further note that the system as presented is 
compatible with many other molecular binders (e.g. antibodies, aptamers, nucleic acids) for 
targeting any molecular target of choice.  
From the data of the capture experiments for iLOV-Doc and yeast cells displaying GFP-Doc in 
diluted human blood plasma samples (Figure 3 and Figure S6B, Supporting information), 
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representative calibration curves for detection of these targets were generated (Figure S7, 
Supporting information) and the detection limits were determined as 311.2 nM (for free iLOV-
Doc) and 0.38 x 106 cells/mL (for yeast cells displaying GFP-DocI). 
Conclusively, we have presented a new system for magnetic capture, separation and enrichment 
of molecular and cellular targets based on co-aggregation between pNIPAm-mNPs and ELP fusion 
proteins. We demonstrate for the first time magnetic actuation of ELPs with a system that has the 
advantages of being rapid, robust, and compatible with point-of-care assays. Our system eliminates 
the requirement of modifying the magnetic nanoparticle surface with affinity biomolecules of any 
kind, and allows for production of pNIPAm-mNPs en masse without any further post-synthesis 
derivatization. The protein capture reagent (in our case, Coh) is produced as a genetic fusion with 
an appropriately designed ELP, and can be purified in a functional form using a chromatography-
free thermo-precipitation method. This workflow means large amounts of both the magnetic 
nanoparticles and biofunctional capture reagents can be obtained without the need for 
chromatography, or post-synthesis modification. In addition to providing a fundamentally new 
approach to magnetic bioseparations, our system effectively streamlines the material-production 
requirements for a wide range of magnetic separations and cell capture applications. We anticipate 
that in the near future, this line of research involving aggregate formation between nanoparticles 
bearing pNIPAm and affinity proteins (e.g. antibodies) bearing ELPs will provide significant 
opportunities in the areas of bioseparations, drug delivery, and in vivo imaging. 
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Experimental details (synthesis of the pNIPAm and pNIPAm-mNPs; cloning, expression and 
purification of the ELP-Coh, iLOV-Doc and Coh-iLOV; LCST determination for the mNPS and 
ELP-Coh; preparation of yeast cells displaying GFP/iLOV-Doc; co-aggregation of the pNIPAm-
mNPs and ELP-Coh and its use for capturing iLOV-Doc or cells displaying GFP-Doc), amino acid 
sequences of all proteins, as well as additional figures (SDS-PAGE, SEC and flow cytometric data) 
(PDF). 
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